VIVS

VivoSim Labs, Inc. Common Stock
VIVS
Market cap $4.19M

1.61 USD

-0.12

6.94%

At close Jun 13, 4:00 PM EDT

After hours

1.57

-0.04

2.48%

1 day

-6.94%

5 days

-10.06%

1 month

-14.36%

3 months

-66.67%

6 months

-66.87%

Year to date

-69.68%

1 year

-85.88%

5 years

-98.80%

10 years

-99.88%

About: VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.

Employees: 14

Healthcare Biotechnology

0

Funds holding %

of 7,296 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

12.64% less ownership

Funds ownership: 16.22% [Q4 2024] → 3.58% (-12.64%) [Q1 2025]

31% less funds holding

Funds holding: 32 [Q4 2024] → 22 (-10) [Q1 2025]

83% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 12

88% less capital invested

Capital invested by funds: $1.15M [Q4 2024] → $143K (-$1M) [Q1 2025]

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 20

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for VIVS.

See Analyst Rankings

Financial journalist opinion

I Missed The Quantum Rally - I Won't Miss The Next One

Here's the next batch of weird science stocks that have market darling potential. I'm tracking five meme-worthy, deep science sectors: brain-computer interfaces, CRISPR/gene editing, organoids, programmable cell therapy, and room-temperature superconductors. Monitor each sector's stocks poised to soar if a major tech player announces a breakthrough.

I Missed The Quantum Rally - I Won't Miss The Next One

VivoSim's NAMKind™ Intestine Wins Blue Ribbon Award at Digestive Disease Week Conference

SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”) announced today that its NAMkind™ platform for intestinal efficacy prediction was recognized with a blue ribbon “Poster of Distinction” award at the Digestive Disease Week Conference (San Diego, CA, May 2-6, 2025). The work describes developing a robust, multicellular in vitro model that closely mirrors human intestinal biology, paving the way for safer and more effective therapies for inflammatory bowel disease (IBD).

VivoSim's NAMKind™ Intestine Wins Blue Ribbon Award at Digestive Disease Week Conference

VivoSim Presents Best-in-Class Liver Toxicology Prediction Results at Digestive Disease Week Conference

SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company”) announced today that its world-leading NAMkind™ platform for liver toxicology prediction, provided as a commercial service to pharma companies, was featured in an oral presentation at the Digestive Disease Week Conference (San Diego, CA, May 2-6, 2025) showing best-in-class predictive power against a set of test liver compounds.

VivoSim Presents Best-in-Class Liver Toxicology Prediction Results at Digestive Disease Week Conference

See News Rankings

Charts implemented using Lightweight Charts™